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The androgen receptor undergoes nuclear import in response
to ligand, but the mechanism by which it undergoes nuclear
export is poorly understood. We developed a permeabilized cell
assay to characterize nuclear export of the androgen receptor in
LNCaP prostate cancer cells. We found that nuclear export of
endogenous androgen receptor can be stimulated by short double-stranded DNA oligonucleotides. This androgen receptor
export pathway is dependent on ATP hydrolysis and is
enhanced by phosphatase inhibition with okadaic acid. Fluorescence recovery after photobleaching in permeabilized cells,
under the conditions that stimulate androgen receptor export,
suggested that double-stranded DNA-dependent export does
not simply reflect the relief of a nuclear retention mechanism. A
radiolabeled androgen was used to show that the androgen
receptor remains ligand-bound during translocation through
the nuclear pore complex. A specific inhibitor to the DNA-dependent protein kinase, NU7026, inhibits androgen receptor
export and phosphorylation. In living cells, NU7026 treatment
increases androgen-dependent transcription from endogenous
genes that are regulated by androgen receptor. We suggest that
DNA-dependent protein kinase phosphorylation of the androgen receptor, or an interacting component, helps target the
androgen receptor for export from the nucleus.

As a member of the nuclear receptor (NR)2 superfamily of
ligand-responsive transcription factors (1), the androgen
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receptor (AR) is composed of an N-terminal transcriptional
activation domain, a central DNA binding domain (DBD), a
hinge region, and a C-terminal ligand binding domain. AR is
important for proper development of male secondary sexual
characteristics and for normal prostate function (2). AR is also
thought to be critical for the tumorigenesis of prostate cancer
(PCa) and for the progression of PCa from an androgen-sensitive to an androgen-insensitive state (3– 8). Thus, in PCa
xenografts in mice, elevation of AR mRNA levels has been correlated with PCa progression to hormone-insensitive status (9).
AR transcriptional regulatory functions are dependent on
the proper subcellular localization of the receptor. AR is
thought to associate with a heat shock protein 90 (hsp90)-based
chaperone complex in the cytoplasm (10) until the binding of
cognate ligand induces a conformational change in AR, chaperone dissociation, and subsequent AR nuclear import (discussed in Refs. 11, 12). Once in the nucleus, AR can bind specific androgen-response elements (AREs) to enhance or repress
transcription of associated androgen-responsive genes. The
type of ligand bound to AR is critical for its regulatory activity,
as agonist and antagonist are known to differentially affect AR
subnuclear localization (11–14) and intranuclear mobility (12,
15). AR can also undergo export from the nucleus (11). The
DBD of AR is sufficient to direct nuclear export of a reporter
protein, and point mutations in the DBD of full-length AR
reduce nuclear export without affecting import (16). The PCa
xenograft LAPC-4 has been used to show that under low
androgen conditions the steady state localization of AR is
different in androgen-dependent and androgen-independent forms of the tumor (17). Thus, defining the mechanisms
responsible for regulating AR protein levels and subcellular
localization could provide insight into the molecular events
that underlie PCa progression.
Multiple signal transduction pathways operate upstream
of the AR and can modulate its transactivation function (18)
A member of the phosphatidylinositol 3-kinase family, DNAdependent protein kinase (DNA-PK), has recently been
implicated in AR transcriptional regulation in human prostate cancer (LNCaP) cells (19). Comprised of a large (⬃470
kDa) catalytic and two Ku regulatory subunits, DNA-PK is
involved in the nonhomologous end-joining response to
DNA damage, V(D)J recombination, and retroviral DNA
integration (20, 21). DNA-PK has been reported to associate
with members of the NR superfamily (22–24) and can phosphorylate the glucocorticoid receptor (GR) in vitro (25, 26).
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Furthermore, the Ku subunits of DNA-PK can be localized to
the promoter of the endogenous AR-responsive PSA gene by
chromatin immunoprecipitation, and they act as AR transcriptional coactivators in reporter assays (19).
In this study we set out to analyze the mechanism of AR
nuclear export by developing an in vitro assay based on digitonin-permeabilized LNCaP cells. Using this assay, we found that
short double-stranded DNA (dsDNA) oligonucleotides stimulated robust AR export in an ATP-dependent reaction. Okadaic
acid (OA) modestly enhanced the reaction and promoted the
phosphorylation of exported AR. Significantly, both AR export
and phosphorylation were prevented by chemical inhibitors of
the phosphatidylinositol 3-kinase kinase family, including an
inhibitor that is specific for DNA-PK. We also found that an
export factor, exportin 5, can stimulate AR export in permeabilized cells independently of DNA-PK. These findings together
with our previous work showing that mitogen-activated protein kinases regulate AR export (27) lead us to conclude that AR
uses multiple pathways to exit the nucleus. We propose that
kinases, including p38, JNK, and DNA-PK, can regulate AR
export, possibly by providing AR with a “license” to exit the
nucleus.

EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—Human prostatic carcinoma
LNCaP cells (28) were cultured in T medium (Invitrogen) containing phenol red and 5% fetal bovine serum. The GFP-AR
plasmid used for fluorescence recovery after photobleaching
(FRAP) analysis and single-cell export assays encodes an N-terminally GFP-tagged form of human AR in a pEGFP-C1 vector
backbone (Clontech). LNCaP cells were transfected using
transfectin (Bio-Rad).
Recombinant Protein Preparation Exportin 5—A pQE60
plasmid (Qiagen) encoding C-terminally His-tagged human
exportin 5 (Addgene plasmid 12553) was transformed into the
TG1 bacterial strain. Following growth to log phase in LB
medium with 2% ethanol, cultures were induced using 300 M
isopropyl 1-thio-␤-D-galactopyranoside overnight at 25 °C.
Cultures were centrifuged and resuspended in 20 mM HEPES,
pH 8, 500 mM NaCl, 10% glycerol, and 14 mM ␤-mercaptoethanol. Resuspension and wash buffers contained 1 mM phenylmethylsulfonyl fluoride and 5 g/ml aprotinin, leupeptin, and
pepstatin. Following three rounds of lysis using a French press,
lysates were clarified and incubated with Talon beads (Clontech) at 4 °C for ⱖ2 h. Talon resin was washed with 20 mM
HEPES, pH 8, 500 mM NaCl, 10% glycerol, 14 mM ␤-mercaptoethanol, and 10 mM imidazole, and then with 20 mM HEPES, pH
8, 200 mM NaCl, 10% glycerol, 7 mM ␤-mercaptoethanol, and 10
mM imidazole. Recombinant exportin 5 was eluted using 20 mM
HEPES, pH 8, 200 mM NaCl, 10% glycerol, 14 mM ␤-mercaptoethanol, and 250 mM imidazole before dialysis into 1⫻ transport buffer (20 mM HEPES, pH 7.4, 110 mM potassium acetate,
2 mM magnesium acetate, 0.5 mM EGTA) supplemented with
10% glycerol, 2 mM DTT, and 1 g/ml aprotinin, leupeptin, and
pepstatin. Exportin 5 was snap-frozen in single-use aliquots.
GST-DBD-Hinge—A pGEX4T3 vector (GE Healthcare)
encoding a fragment of AR that includes the DBD and hinge
domains (residues 549 – 671) was transformed into BL21 cells.
APRIL 18, 2008 • VOLUME 283 • NUMBER 16

Following growth to log phase, protein expression was induced
with 1 mM isopropyl 1-thio-␤-D-galactopyranoside in the presence of 2% ethanol for 3 h at room temperature. Pelleted cells
were resuspended in PBS supplemented with protease inhibitors. Following French press-mediated lysis, lysates were clarified and incubated with glutathione beads for 1.5 h at 4 °C. The
bound fraction was washed with PBS containing 1% Triton
X-100, then washed with PBS containing 500 mM NaCl, and
then washed with PBS alone. GST-AR-DBD-Hinge protein was
eluted with 100 mM Tris, pH 8, 10 mM glutathione, 1 mM MgCl2,
0.1 mM EDTA, 1 mM DTT, aprotinin, leupeptin, and pepstatin.
Dialysis into 1⫻ transport buffer (20 mM HEPES, pH 7.4, 110
mM potassium acetate, 2 mM magnesium acetate, 0.5 mM
EGTA) containing 1 mM DTT preceded snap freezing in singleuse aliquots.
In Vitro AR Export Assay—The assay was based on selective
permeabilization of the plasma membrane of cultured cells
with digitonin, an approach used to study protein import and
export mechanisms (29). LNCaP cells expressing endogenous
AR were supplied with 1–10 nM synthetic androgen (R1881;
PerkinElmer Life Sciences) for 1–3 h prior to a wash with phosphate-buffered saline (Invitrogen). Cells were subjected to a
brief trypsinization (0.05% trypsin/EDTA (Invitrogen)) that
was quenched with serum-containing medium, then subjected
to gentle centrifugation (⬃200 ⫻ g) before resuspension in icecold 1⫻ transport buffer. Cells were permeabilized on ice for
6 – 8 min with 50 g/ml high purity digitonin (Calbiochem) in
ice-cold complete transport buffer (CTB: 1⫻ TB containing 2
mM DTT, 1 g/ml aprotinin, and 0.5 g/ml leupeptin and pepstatin). Cells were then washed with ice-cold CTB and aliquoted into standard polystyrene tubes commonly used for
DNA transfection (Falcon 352058). Ice-cold export reaction
mixes were added to aliquots of permeabilized cells on ice. Final
reaction volume was ⬃125 l (100-l reaction mix and 25-l
cell suspension); final permeabilized cell concentration in each
reaction was ⬃5 ⫻ 106 cells/ml. The tubes containing the permeabilized cells and reaction mixes were incubated at 30 °C for
20 –30 min. Following the incubation, reaction components
were centrifuged (⬃18,000 ⫻ g for 12 min) to isolate the reaction supernatant (containing the exported AR fraction) from
the cell pellet (containing the nonexported, nuclear AR). Equal
volumes of reaction supernatants were then separated on 7.5%
acrylamide SDS-polyacrylamide gels. Following SDS-PAGE
separation, proteins were transferred onto PVDF membranes
(Millipore) and immunoblotted using the polyclonal ␣-AR
antibody PG-21 (directed against the N-terminal 21 amino acid
residues of AR (Upstate)), providing a semi-quantitative measure of the amount of AR exported during the assay. Comparison of the exported fractions with cell pellets (nuclei) in multiple experiments established that equivalent numbers of
permeabilized cells were dispensed and recovered under different conditions and that on average ⬃40% of LNCaP AR was
exported in a 30-min reaction (data not shown).
In vitro export assays conducted in the presence of CTB
alone served as negative control for AR export. Our energyregenerating system (ERS) consisted of bovine serum albumin
(5 mg/ml final in export reaction), creatine phosphokinase (80
units/ml final), creatine phosphate (1.6 mg/ml final), ATP
JOURNAL OF BIOLOGICAL CHEMISTRY
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(1 mM final), GTP (1 mM final), and aprotinin. Nonhydrolyzable
nucleotide analogs AMP-PNP and GMP-PNP were also used at
1 mM final concentration. Okadaic acid (Calbiochem) was used
at a final concentration of 200 nM. Casodex (10 M; Fisher),
wortmannin (20 M (MP Biomedicals)), LY294002 (50 M (Calbiochem)), and NU7026 (2.5 M (Sigma)) were added to LNCaP
cells 1–2 h prior to the start of the in vitro export assay. Chemical inhibitors were routinely maintained in pre-export wash
buffers and in export reactions. For export assays in the absence
of agonist, cells were washed with phenol red-free RPMI
(Invitrogen) containing 5% charcoal-stripped serum, and then
incubated in this medium for 6 –24 h prior to permeabilization
and in vitro export assays.
For phosphatase treatment of exported AR, export reactions
were first carried out in the presence of ERS, OA, and ARE (1
M). Following centrifugation, the export supernatants (36 l)
were treated with Antarctic phosphatase (10 units; PerkinElmer
Life Sciences) for 2 h at 37 °C in the presence of the manufacturer’s supplied buffer (final 1⫻ concentration). Reaction components were subjected to SDS-PAGE, and AR was immunoblotted with the PG-21 antibody.
For in vitro export assays using [3H]R1881, LNCaP cells were
incubated in the presence of 2 nM [3H]R1881 (PerkinElmer Life
Sciences) for 1–3 h prior to washing and cell permeabilization.
In vitro export reactions ensued at 30 °C for 30 min. Reaction
supernatants containing the exported AR fraction were then
collected, applied to Whatman paper, dried, and measured by
scintillation counting. For immunoprecipitations, reaction
supernatants were incubated with control resin or AR-21
anti-AR resin in the presence of 0.1% Triton X-100 for 4 h at
4 °C. Resins were washed five times in complete transport
buffer containing 0.1% Triton X-100 prior to release of bound
[3H]R1881 with 2% SDS at 90 °C for 10 min. Released fractions
were applied to Whatman paper, dried, and measured by scintillation counting.
For in vitro export assays followed by detergent extraction,
LNCaP cells were subjected to standard export reactions prior
to centrifugation and harvest of reaction supernatants containing the exported AR fraction. Cell pellets containing residual,
nonexported AR were then subjected to extraction with 0.5%
Triton X-100 in complete transport buffer supplemented with
bovine serum albumin (5 mg/ml final), glycerol (0.5% final), and
aprotinin, for 20 min on ice. Subsequent centrifugation yielded
supernatant (detergent-sensitive) and pellet (detergent-resistant) fractions. In Fig. 6C (Triton in the Export Rxn samples),
0.5% Triton X-100 was included during standard export reactions to disrupt the nuclear envelope and yielded a single
released AR fraction.
Recombinant exportin 5 was used at a final concentration of
0.1 and 0.2 mg/ml. Dialysis buffer obtained from the preparation of recombinant exportin 5 served as negative control in the
export reactions.
For in vitro AR export in adherent cells, LNCaP cells were
plated on glass coverslips (Fisher) coated with poly-D-lysine
(Sigma) and grown in T medium containing phenol red and
supplemented with 5% fetal bovine serum. Following treatment
with 10 nM R1881, cells were washed three times (4 min/wash)
with ice-cold TB, permeabilized with 50 g/ml digitonin in
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ice-cold CTB for 6 – 8 min, and then washed again three times
with ice-cold CTB. Export reaction mixes were supplied to the
cells before incubation at 30 °C for 20 –30 min. Cells were
washed two more times with ice-cold CTB prior to fixation with
3.7% formaldehyde.
In antibody access experiments to test the integrity of the
nuclear envelope during in vitro export assays, an antibody to
the nuclear protein RCC1 (Santa Cruz Biotechnology) was
included in the export reaction mix (7 g/ml final). As a positive
control for envelope disruption, 0.2% Triton X-100 was also
included in the export reaction. Following the export assay,
washes, and fixation, cells were then permeabilized with 0.2%
Triton X-100 and subjected to standard immunofluorescence
processing using an anti-AR primary antibody (AR-21) and secondary antibodies to both the anti-RCC1 and anti-AR primary
antibodies. Cells were mounted and viewed using a Nikon
Eclipse E800 upright microscope.
DNA Oligonucleotides—Oligonucleotides used to stimulate
AR export in vitro are from Sigma Genosys. The ARE duplex
(duplex a, see Fig. 7A) contains both half-sites of the ARE in the
C(3)1 intron of the prostatic binding protein gene (30). The
mutant ARE duplex (duplex b) contains four point mutations
within the 12-residue positions comprising the tandem of ARE
half-sites (30). Oligonucleotides c and d are the sense and antisense strand components, respectively, of the wild-type ARE
duplex (duplex a). Duplexes f– h are derivatives of the wild-type
ARE duplex. In duplex i, the two ARE half-sites are separated by
a noncomplementary bubble, 12 residues in length on each
duplex strand. In oligonucleotide j, the upstream ARE half-site
is adjoined to a 13-nucleotide noncomplementary loop (see Fig.
7A for schematic representations of these oligonucleotides).
The NRE duplex is a derivative of the ARE duplex and harbors
an NRE1 sequence (26) instead of an ARE. The ARE-NRE
duplex contains an NRE1 sequence and an ARE in cis. NS1,
NS2, and NS3 are intended as nonspecific duplexes that harbor
neither an ARE nor an NRE1 sequence.
FRAP Analysis and AR Export in Single Cells—LNCaP cells
were grown on Delta T dishes (Fisher) coated with poly-D-lysine. Following expression of GFP-AR, cells were treated with
R1881 and subjected to standard permeabilization and washes
with complete transport buffer on ice. Cells were then placed
on a Bioptechs stage warmer, and GFP-AR-expressing cells
were identified using the wide field mode of a Zeiss LSM 510
Meta confocal laser scanning microscope, and export reaction
mixes were added to cells. For single-cell export assays, nuclear
GFP fluorescence intensity was recorded immediately prior to
and immediately following a 30-min export reaction at 37 °C.
The ratio of these two values (plotted in Fig. 4D) provides a
measure of nuclear GFP fluorescence lost, and therefore of
GFP-AR nuclear export, during the reaction. For FRAP measurements, recovery of GFP fluorescence into the photobleached area was monitored in increments of 2.5 min. Recovery curves represent the ratio of the fluorescence intensity
within the photobleached rectangular area to the nuclear fluorescence intensity outside this photobleached area plotted as a
function of time. Following addition of an export reaction mix,
up to six recovery curves per dish were generated sequentially,
each in a separate cell. All recovery curves for a given export
VOLUME 283 • NUMBER 16 • APRIL 18, 2008
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reaction condition were averaged, and a representative recovery curve is plotted for each condition in Fig. 4B. The t1⁄2 value
(Table 1) indicates the time at which the half-maximal amount
of fluorescence recovery into the photobleached area has
occurred, under a given reaction condition.
DNA Oligonucleotides—Oligonucleotide sequences are as
follows: duplex a, sense, GGGAGCTTACATAGTACGTGATGTTCTCAAGGTCGA, and antisense, TCTCGACCTTGAGAACATCACGTACTATGTAAGCT; duplex b (residues
mutated relative to duplex a are in boldface), sense, GGGAGCTTACATTGTTCTTGAGGTTCTCAAGGTCGA, and antisense, TCTCGACCTTGAGAACCTCAAGAACAATGTAAGCT; oligonucleotide c (identical to the sense strand of duplex
a), GGGAGCTTACATAGTACGTGATGTTCTCAAGGTCGA; oligonucleotide d (identical to the antisense strand of
duplex a), TCTCGACCTTGAGAACATCACGTACTATGTAAGCT; duplex e, sense, AGCTTACATAGTACGTGATGTTCTCAAGGTCGACT, and antisense, TCGACCTTGAGAACATCACGTACTATGTAAGCTGGG; duplex f, sense,
GGGAGCTTACATAGTACGTGATGTTCTCAAGGTCGACT, and antisense, TCTCGACCTTGAGAACATCACGTACTATGTAAGCTGGG; duplex g, sense, GGGAGCTTACATAGTACGTGATGTTCTCAAGGTCGAGA, and antisense,
TCTCGACCTTGAGAACATCACGTACTATGTAAGCTCCC; duplex h, sense, CATAGTACGTGACCCCCCCCCCCCTGATGTTCTCAA, and antisense, TTGAGAACATCACCCCCCCCCCCCTCACGTACTATG; oligonucleotide i, CATAGTACGTGACCCCCCCCCCCCTCACGTACTATG; and
duplex j, sense. CGCGC(I26)CGCGC, and antisense, GCGCG(C26)GCGCG; NRE, sense, GGGAGCTAACTGAGAAAGAGAAAGACGACAGGTCGA, and antisense, TCTCGACCTGTCGTCTTTCTCTTTCTCAGTTAGCT; ARE-NRE, sense,
AACTGAGAAAGAGAAAGACGAGCTTACATAGTACGTGATGTTCTCAAGGT, and antisense, ACCTTGAGAACATCACGTACTATGTAAGCTCGTCTTTCTCTTTCTCAGTT; NS1, sense, TCGAGATGGATTATAAAGCATTTGATAATCTTTAAT, and antisense, CTAGATTAAAGATTATCAAATGCTTTATAATCCATC; NS2, sense, GTCCATCTTGTCGTCTTGAGAAATGTTATGAAGCAGGG,
and
antisense, CCCTGCTTCATAACATTTCTCAAGACGACAAGATGGAC; and NS3, sense, AGAAAAAATCCCACATCCTGCTCAGAGCGCTTCTACCAGCTCACC, and antisense, GGTGAGCTGGTAGAAGCGCTCTGAGCAGGATGTGGGATTTTTTCT. The fluorescent ARE duplex used in
Fig. 1C contains a fluorescein moiety on the 5⬘ end of the
antisense strand of the wild-type ARE duplex (duplex a).
Real Time RT PCR—Real time RT PCR analysis was done on
an iCycler optical system (Bio-Rad) using the IQ SYBR Green
PCR master mix. LNCaP cells were pretreated with NU7026 for
16 h and then the cells were untreated or treated with 1 nM
R1881 for 24 h. Total RNA was extracted from cells using the
RNeasy kit (Qiagen). DNase I treatment was performed directly
on the RNeasy mini column with 27 Kunitz units of DNase I
(Qiagen) for 15 min at room temperature according to the Qiagen protocol. RNA was quantified using Ribogreen (Molecular
Probes). 500 ng of RNA was reverse-transcribed in a 20-l reaction volume using the iScript cDNA synthesis kit (Bio-Rad)
according to the manufacturer’s protocol. The human-specific
APRIL 18, 2008 • VOLUME 283 • NUMBER 16

PCR primers used were as follows: forward PSA, 5⬘-TGGTGCATTACCGGAAAGTGGATCA-3⬘, and reverse PSA 5⬘-GCTTGAGTCTTGGCCTGGTCATTTC-3⬘; forward S100P, 5⬘-ATGACGGAACTAGAGACAGCC-3⬘, and reverse S100P 5⬘-AGGAAGCCTGGTAGCTCCTT-3⬘; forward FKBP51, 5⬘-CATCAAGGCATGGGACATTGG-3⬘, and reverse FKBP51 5⬘-TCGAGGGAATTTTAGGGAGACT-3⬘; forward PDF, 5⬘-GGGCAAGAATCTCAGGACGG-3⬘, and reverse PDF 5⬘-TCTGGAGTCTTCGGAGTGCAA-3⬘; and forward ␤-glucuronidase, 5⬘-CCGACTTCTCTGACAACCGACG-3⬘, and reverse ␤-glucuronidase, 5⬘-AGCCGACAAAATGCCGCAGACG-3⬘. Nonreversed transcribed
RNA was subject to PCR as a control; no DNA contamination
was observed. Primer annealing temperatures were 66 °C
(PSA), 58 °C (S100P), 60 °C (FKBP51), 58 °C (PDF), or 68 °C
(␤-glucuronidase). Mean starting quantity of each androgeninduced gene is normalized to mean starting quantity ␤-glucuronidase; this ratio (with standard error for the ratio) is shown
in Fig. 9, A–D, for a representative experiment in which each
sample is tested in duplicate.

RESULTS
AR Export in Permeabilized LNCaP Cells—We developed a
permeabilized cell assay to investigate the mechanism(s) of AR
export. In this assay, cultured LNCaP cells were pretreated with
the synthetic androgen R1881 to induce nuclear import of
endogenous AR. Cells were harvested, washed, and treated with
digitonin to selectively permeabilize the plasma membrane.
Permeabilized cells were then supplemented with reaction
mixes to stimulate nuclear export of AR into the reaction supernatant, which was examined by immunoblotting with affinitypurified anti-AR antibody. In the course of optimizing reaction
conditions for the assay, we tested whether a dsDNA oligonucleotide containing an ARE (Fig. 1A) could improve cytosol-dependent nuclear export by relieving presumed nuclear retention of AR. This approach had been used by Kehlenbach et al.
(31) to improve cytosol-dependent NFAT export in permeabilized cells. Unexpectedly, we found that ARE together with an
energy-regenerating system (ERS) stimulated robust AR export
without the addition of cytosolic factors (Fig. 1B). Fluorescently
labeled ARE entered the nuclei of digitonin-permeabilized
LNCaP cells during the export assay, which is consistent with
ARE stimulating AR export from within the nuclei (Fig. 1C).
We also verified that the nuclear envelope remains intact under
conditions that promote AR export. An antibody to the nuclear
protein RCC1 failed to detect its antigen unless the nuclear
envelope was disrupted by Triton X-100 treatment (Fig. 1D).
Together, these data show that ARE stimulates energy-dependent AR translocation through the nuclear pore complex
(NPC).
ARE-dependent AR Export Requires ATP Hydrolysis—Depending on the export substrate, ATP (31, 32) and/or GTP (33)
can stimulate nuclear export in permeabilized cells. As our
ERS contains both ATP and GTP, we tested whether one or
both nucleotides is required for AR export. ATP, but not
GTP, stimulated AR export in the presence of the ARE oligonucleotide (Fig. 2). The nonhydrolyzable ATP analog
AMP-PNP did not support AR export, and the nonhydrolyzable GTP analog GMP-PNP did not inhibit export stimulaJOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 2. ATP hydrolysis is required for ARE-dependent AR nuclear
export. Permeabilized LNCaP cells were subjected to standard AR in vitro
export assays in the presence of ARE (1 M) and the presence (lane 2) or
absence (lane 1) of a complete energy-regenerating system. ATP, GTP, AMPPNP, and/or GMP-PNP were added in the combinations shown (each 1 mM
final). Reaction supernatants containing the exported AR fraction were
immunoblotted using the anti-AR PG-21 antibody.

FIGURE 3. OA enhances ARE-dependent AR nuclear export and stimulates phosphorylation of exported AR. A, standard AR in vitro export
assays were conducted in the presence of ARE (1 M), ERS, and/or OA (200
nM) as shown. Reaction supernatants containing the exported AR fraction
were immunoblotted with the anti-AR PG-21 antibody. B, permeabilized
LNCaP cells were first treated with ERS/OA/ARE to stimulate AR nuclear
export. Reaction supernatants containing the exported AR fraction (lane
1) were then incubated in the presence of buffer (Buf, lane 2) or phosphatase (Ppase, lane 3) for 2 h at 37 °C. C, standard in vitro AR export assays
were conducted in the presence of ERS/OA/ARE (lanes 2– 8) and harvested
at the times indicated. A control reaction in the presence of buffer alone
(lane 1) continued for 30 min. Exported AR fractions were immunoblotted
using the PG-21 antibody.

FIGURE 1. A double-stranded DNA oligonucleotide containing an ARE stimulates nuclear export of endogenous AR in permeabilized LNCaP cells.
A, schematic representation of a 33-bp double-stranded oligonucleotide (ARE)
that contains the C3(1) ARE (70) and possesses two 5⬘ overhangs. B, ARE (1 M)
and an ERS (contains ATP, GTP, creatine phosphate, creatine phosphokinase, and
bovine serum albumin) were added in the combinations shown to permeabilized LNCaP cells to induce AR nuclear export in vitro (as described under “Experimental Procedures”). Reaction supernatants containing the exported AR fraction
were subjected to SDS-PAGE (7.5% acrylamide) and immunoblotted using the
anti-AR PG-21 antibody. C, adherent LNCaP cells were permeabilized with digitonin and subjected to standard in vitro export reactions in the presence of a fluorescein-labeled ARE. Fluorescein (FITC) and 4⬘,6-diamidino-2-phenylindole (DAPI)
channels show fluorescent ARE and DNA localization, respectively. D, standard in
vitro assays using adherent LNCaP cells were conducted in the presence or
absence of 0.2% Triton X-100 (TX-100). All export reactions contained 7 g/ml of
anti-RCC1 antibody. Cells were then washed, fixed, exposed to a secondary antibody against the anti-RCC1 primary antibody, and analyzed using immunofluorescence microscopy.

tion by ATP (Fig. 2). Our results indicate that ATP hydrolysis, and not GTP hydrolysis, is rate-limiting for AREdependent AR export.
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This ATP requirement could reflect the involvement of a
kinase(s) or protein chaperone(s) in ARE-stimulated AR
export. Because phosphatase activity has been implicated in the
regulation of GR nucleocytoplasmic trafficking (34), we tested
the phosphatase inhibitor okadaic acid in our permeabilized
cell assay. We found that OA modestly enhanced AR export
and caused an upward shift in AR electrophoretic mobility (Fig.
3A, compare lanes 3 and 6). This AR mobility shift is strongly
dependent upon ERS and ARE (Fig. 3A) and can be reversed by
alkaline phosphatase treatment of exported AR (Fig. 3B). Thus,
AR undergoes phosphorylation during the export reaction in
the presence of ERS/OA/ARE. Time course analysis of AR
export suggested that there are multiple pools of exported AR
under this reaction condition (Fig. 3C). The faster migrating
form of AR is exported within 4 min of the start of the assay.
Within 8 –12 min, a slower migrating form of AR appears in the
exported fraction; the amount of this form of AR increases as a
function of time (Fig. 3C, compare lanes 3– 8).
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TABLE 1

FIGURE 4. Single-cell analysis of GFP-AR in permeabilized LNCaP cells.
A, LNCaP cells expressing GFP-AR were treated with 10 nM R1881, permeabilized, and subjected to FRAP analysis in the presence of standard
export reaction mixes. In the representative cell shown here, recovery of
GFP-AR into the bleached zone was visualized in the presence of ERS/OA/
ARE (see “Experimental Procedures” for further details). B, FRAP recovery
curves of intra-nuclear GFP-AR were generated using the different export
reaction mixes shown. Intact cells were not permeabilized; EOA signifies
an export reaction mix of ERS/OA/ARE. Each recovery curve was generated
from a single cell that represents the behavior of all cells sampled under a
particular reaction condition. C, LNCaP cells expressing GFP-AR were
treated with 10 nM R1881, permeabilized, and subjected to standard in
vitro export assays. Individual cells expressing GFP-AR were monitored for
the loss of nuclear GFP fluorescence as a measure of GFP-AR nuclear
export. Nuclear GFP fluorescence is shown in representative cells before (0
min) and after (30 min) an export reaction in the presence of buffer alone
(Buffer) or in the presence of ERS/OA/ARE. D, LNCaP cells expressing
GFP-AR were treated as in C. The amount of GFP fluorescence remaining in
the nucleus after an in vitro export assay, compared with total nuclear GFP
fluorescence prior to the assay, was calculated for individual cells in the
presence of different export reaction mixes. The average value of this
fraction is shown for all cells under a particular reaction condition.
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Reaction
condition

t1⁄2

Mobile
AR fraction

Exported
AR fraction

s

%

%

Buffer
ERS
ARE
ERS/ARE
ERS/OA/ARE

15.8 ⫾ 2.1
51.0 ⫾ 8.3
25.6 ⫾ 5.1
26.3 ⫾ 2.5
24.7 ⫾ 5.6

40 ⫾ 5
36 ⫾ 3
46 ⫾ 4
59 ⫾ 3
43 ⫾ 5

0 ⫾ 12
6⫾5
38 ⫾ 7
55 ⫾ 5
64 ⫾ 4

FRAP Analysis Suggests That AREs Do Not Promote Export
Simply by Relief of Retention—Theoretically, AREs might promote AR export by relief of AR nuclear retention on chromatinbinding sites or by induced changes in AR structure and/or
subnuclear compartmentalization. To investigate this question
further, we carried out export assays in single LNCaP cells to
establish that the requirements for GFP-AR export are the same
as for unfused, endogenous AR (Fig. 4D, compare with Fig. 3A).
To address whether AR is subject to nuclear retention in our
assay, we analyzed the intranuclear mobility of GFP-AR using
FRAP. LNCaP cells expressing GFP-AR were permeabilized
with digitonin, supplemented with different export reaction
mixes, subjected to photobleaching, and monitored for fluorescence recovery (Fig. 4B). The recovery rate of GFP-AR
(expressed as t1⁄2 values) did not correlate with the level of
GFP-AR nuclear export under different reaction conditions.
For example, maximal intranuclear mobility of GFP-AR was
observed in the presence of ERS alone; however, this condition
promoted only near-background levels of GFP-AR export
(Table 1). These data suggest that ARE-dependent AR export
does not simply reflect relief of nuclear retention.
Nuclear Export of Androgen-bound AR—NRs including GR
(35), AR (11), and the progesterone receptor (PR) (36) undergo
ligand-dependent nuclear import. Some NRs undergo nuclear
export following ligand exposure and subsequent withdrawal
(11, 37–39), but whether ligand dissociation is required for NR
export is unknown. To address this question, we pretreated
LNCaP cells in culture with radiolabeled androgen ([3H]R1881,
2 nM) to provide a readout for androgen-bound AR. Scintillation counting revealed that ARE stimulated the release of
[3H]R1881 into the export reaction supernatant (Fig. 5A). Furthermore, the amounts of [3H]R1881 released into the supernatant under different export conditions were similar to the
amounts of AR exported from the nucleus in nonradioactive
assays (compare Fig. 5A with Fig. 3A). We established by immunoprecipitation and scintillation counting that the [3H]R1881
released into the supernatant was bound to AR (Fig. 5B). These
data indicate that androgen dissociation is not a prerequisite for
AR nuclear export and that AR remains ligand-bound during
export via the dsDNA-dependent export pathway.
Inhibition of Phosphatidylinositol 3-Kinase Reduces AR
Export and AR Phosphorylation—ARE stimulation of both AR
export and AR phosphorylation suggested that a nuclear kinase
might be activated by ARE in the permeabilized cell assay. The
DNA-dependent protein kinase (DNA-PK) merited consideration for two reasons. DNA-PK kinase activity is stimulated by
dsDNA in vitro (40 – 42), and DNA-PK has been reported to
associate with AR in LNCaP cells (19). To address whether
DNA-PK is involved in ARE-dependent AR export, we tested
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 5. Ligand dissociation is not a prerequisite for AR nuclear export.
A, LNCaP cells were supplied with [3H]R1881 (2 nM) prior to standard in vitro
export assays under the reaction conditions shown. Reaction supernatants
containing the exported AR fraction were harvested and subjected to scintillation counting to determine the amount of [3H]R1881 liberated from permeabilized cells during the export assay. Values from a representative experiment are shown. B, LNCaP cells were treated as in A, except that reaction
supernatants containing the exported AR fraction were immunoprecipitated
with anti-AR AR-21 antibody. Immunoprecipitates were then washed,
extracted (as described under “Experimental Procedures”), and subjected to
scintillation counting to determine the amount of [3H]R1881 associated with
AR in the exported fraction. Values from a representative experiment, in
which background [3H]R1881 binding to control resin has been subtracted to
yield corrected values of [3H]R1881 binding to the anti-AR resin, are shown.

wortmannin and LY294002 in the AR export assay. These
inhibitors are known to target phosphatidylinositol 3-kinase
family members, including DNA-PK (43, 44). In the presence of
ERS/OA/ARE, wortmannin and LY294002 each reduced AR
export to a level similar to that obtained in the presence of ARE
alone (Fig. 6, A and B, rows 1 and 2, compare 2nd and 4th lanes).
Wortmannin and LY294002 also blocked the mobility shift of
exported AR observed in the presence of ERS/OA/ARE (Fig. 6,
A and B).
We next performed biochemical extraction to gain insight
into the role of AR compartmentalization in ARE-stimulated
AR export. We harvested the supernatants from export reactions (Fig. 6C, Exported) and then treated the same LNCaP
nuclei with Triton X-100 to generate Triton-released and Triton-resistant fractions. In permeabilized cells, AR is initially
found in a Triton-resistant compartment (Fig. 6C, lane 1, Control). The amount of AR in the Triton-resistant compartment
changes little with the addition of ERS alone or ARE alone (Fig.
6C, lanes 2 and 3, Control). However, ERS and ARE in combination significantly reduce the amount of AR in the Tritonresistant compartment (Fig. 6C, lanes 4 and 5, Control). In this
assay, wortmannin addition increases the amount of AR in the
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FIGURE 6. Wortmannin and LY294002 inhibit ARE-dependent AR export
and phosphorylation. A, LNCaP cells were treated with 10 nM R1881 alone or
in addition to 20 M wortmannin prior to standard in vitro export assays in the
presence of ERS, OA, and/or ARE as shown. Exported AR fractions were immunoblotted with the PG-21 antibody. B, LNCaP cells were treated with 10 nM
R1881 alone or in addition to 50 M LY294002 prior to standard in vitro export
assays. C, LNCaP cells were treated with 10 nM R1881 alone or in combination
with 20 M wortmannin. Cells were then subjected to standard in vitro export
assays under the conditions shown, and reaction supernatants containing
the exported AR fraction were harvested. Cell pellets containing residual
nuclear, nonexported AR were then subjected to extraction with 0.5% Triton
X-100 on ice for 20 min. After centrifugation, the extracted (Triton Released)
and nonextracted (Triton Resistant) AR fractions were harvested and subjected to SDS-PAGE along with the exported AR fractions and detected by
immunoblotting with the PG-21 antibody. For Triton in the Export Rxn samples, LNCaP cells were subjected to standard in vitro export assays in the
presence of 0.5% Triton X-100, i.e. detergent was added at the start of the
export reaction rather than at a post-export extraction step.

Triton-resistant fraction (Fig. 6C, lanes 4 and 5, compare Control and ⫹Wortmannin), and it blocks the upward electrophoretic mobility shift of AR. These data suggest that a wortmannin-sensitive kinase regulates an early step in the AR
export pathway. Together with findings presented below, these
results implicate DNA-PK in the regulation of dsDNA-dependent AR export.
Evidence That DNA-PK Activation Promotes AR Export in
Vitro—We sought to characterize what oligonucleotide
sequence and/or structure is necessary for AR export stimulation (Fig. 7). Our panel of oligonucleotides included duplexes
similar to ones used by other laboratories to activate DNA-PK
in vitro (40 – 42, 45). An ARE oligonucleotide synthesized with
VOLUME 283 • NUMBER 16 • APRIL 18, 2008
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pared with a wild type ARE oligonucleotide (duplex a, Fig. 7B, lane 2).
The observation that AR export can
be stimulated by a mutant ARE suggested the reaction is not sequencespecific, but a duplex comprised
predominantly of inosine and cytosine had no activity in the assay
(duplex j, Fig. 7B, lane 15). Reducing
the concentration of ARE and
mutant ARE 10-fold (100 nM final)
resulted in significantly less AR
export (Fig. 7B, lanes 4 and 5). Neither of the single-stranded oligonucleotides that together comprise the
ARE duplex were alone able to stimulate AR export or AR mobility shift
(Fig. 7B, duplexes c and d, lanes 6
and 7). As the ARE we used contains
5⬘ overhangs, we tested whether oliFIGURE 7. Oligonucleotides with differing sequence and structure can stimulate AR export and phospho- gonucleotide end structure is
rylation. A, schema of different DNA oligonucleotides used in B to stimulate AR export in vitro. dsDNA oligonucleotide (a) is the standard ARE; b is a mutant ARE containing four point mutations within the pair of ARE important for ARE-stimulated AR
half-sites (30); c and d are the sense and antisense strand components, respectively, of the standard ARE; e is a export and phosphorylation. ARE
modified ARE possessing two 3⬘ overhangs; f is a modified ARE possessing two 3⬘ overhangs and two 5⬘
overhangs; g is a modified ARE possessing two blunt ends; h is a modified ARE with a noncomplementary duplexes possessing two 5⬘ and two
bubble between both half-sites of the ARE; i is a hairpin oligonucleotide containing within its complementary 3⬘ overhangs (Fig. 7B, duplex f, lane
dsDNA region one of the two half-sites of the ARE; and j is a dsDNA oligonucleotide containing an internal 10) or blunt ends (duplex g, lane 11)
stretch of 26 inosine:cytosine pairs flanked by five C:G pairs on each end of the oligonucleotide. B, LNCaP cells
were pretreated with 10 nM R1881 and subjected to standard in vitro export assays in the presence of the stimulated AR export and mobility
oligonucleotides described in A. Oligonucleotides were included at 1 M except in lanes 4 and 5 (100 nM) and shift similarly to ARE (duplex a,
lanes 6 and 7 (2 M). Exported AR fractions were immunoblotted with the PG-21 antibody.
lane 2). Finally, a stem-loop structure (Fig. 7B, oligo i, lane 13) and a
duplex containing an internal bubble (duplex h, lane 12) both
failed to stimulate AR export. Our results suggest ARE treatment stimulates export both by direct binding to AR and by
activation of DNA-PK.
As an additional test for the involvement of DNA-PK in
dsDNA-stimulated AR export, we employed the chemical
inhibitor NU7026. When used at a concentration (2.5 M) to
inhibit DNA-PK but not phosphoinositide 3-kinase-related
protein kinase subfamily kinases ATM or ATR (44, 46),
NU7026 inhibited AR export and abolished the electrophoretic
mobility shift of exported AR induced by ERS/OA/ARE (Fig. 8).
We also tested NU7026 in the presence of a modified ARE in
which the two ARE half-sites were exchanged for a sequence
FIGURE 8. A DNA-PK inhibitor blocks ARE-dependent AR export and
phosphorylation. LNCaP cells were treated with 10 nM R1881 alone or in element that binds the Ku regulatory dimer of the DNA-PK
combination with 2.5 M NU7026 prior to permeabilization and standard in complex (denoted NRE; see Ref. 26). The NRE duplex stimuvitro export assays in the presence of ERS, OA, and/or dsDNA as shown.
lated AR export in the presence of ERS and OA, and it also
Exported AR fractions were immunoblotted using anti-AR PG-21. In the panel
shown, the left-hand column indicates the reaction mix components that are induced the electrophoretic mobility shift observed in the prescombined with the dsDNA oligonucleotide (1 M) in the top row to stimulate ence of ARE (Fig. 8). We also examined whether AR export
AR export. NRE is a modified ARE in which the ARE has been exchanged for a
negative regulatory element-1 sequence (26). ARE-NRE is a modified ARE con- could be stimulated by an oligonucleotide duplex containing
taining a negative regulatory element-1 sequence in cis to the ARE. NS1, NS2, AR- and Ku-binding sequences in cis, reasoning that this
and NS3 are dsDNA oligonucleotides that do not contain an ARE. All gel lanes duplex might function as a scaffold and facilitate an interaction
shown are from the same film exposure. Therefore, although absolute
amounts of exported AR cannot be compared directly between the two cell between AR and DNA-PK. This oligonucleotide (denoted AREpopulations, the amounts of exported AR can be compared between differ- NRE) stimulated AR export and mobility shift with about the
ent rows within the same cell population.
same efficiency as the ARE oligonucleotide. Interestingly, the
NRE oligonucleotide induced AR export without generating
four point mutations in the ARE half-sites (Fig. 7A, duplex b) the faster migrating form of AR routinely observed in the pres(30) stimulated AR export and phosphorylation (Fig. 7B, lane ence of the ARE oligonucleotide. Three dsDNA oligonucleo3), although the level of export was slightly reduced when com- tides unrelated to the ARE also stimulated NU7026-sensitive
APRIL 18, 2008 • VOLUME 283 • NUMBER 16
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AR export (Fig. 8, see NS1–3 in the presence of ERS/OA, Control versus ⫹NU7026). These data indicate that nuclear export
promoted by dsDNA is mediated through DNA-PK.
NU7026 Enhances Androgen-dependent Transcription in
Prostate Cancer Cells—To address whether DNA-PK inhibition affects AR transcriptional activity, we treated LNCaP cells
with NU7026 and assayed the transcript levels of four genes
whose expression is regulated by androgen and AR. Real time
PCR analysis revealed that NU7026 slightly enhanced (20%
increase) AR-dependent transcription from the PSA gene (Fig.
9A). NU7026 increased AR-dependent transcription of the
S100P gene to a greater extent (⬃5-fold; Fig. 9B). Intermediate
effects were measured for the PDF and FKBP51 genes, as
NU7026 enhanced the androgen-induced transcript levels of
these genes ⬃2-fold (Fig. 9, C and D). These results, together
with our in vitro biochemical data and previous work showing
that DNA-PK binds to AR (19), indicate a functional link
between DNA-PK and AR.
Exportin-mediated AR Export—Nuclear import and export
of most proteins is mediated by transport receptors belonging
to the importin ␤ superfamily (47). We tested exportins 4 –7
(prepared by in vitro translation) for RanGTP-dependent binding to the GST-DBD-Hinge protein immobilized on glutathione beads. All four exportins displayed Ran-sensitive binding to
the AR DBD-Hinge (data not shown), but only one of these
receptors, exportin 5, stimulated AR export from the nucleus of
digitonin-permeabilized LNCaP cells (Fig. 10A). Exportin 5-dependent export was inhibited by including excess AR GSTDBD-Hinge protein in the permeabilized cell assay, which indicates the DBD-hinge contains the signal for exportin
5-mediated AR export (Fig. 10B). Unexpectedly, AR export in
this setting did not require the addition of recombinant Ran,
but this may indicate our permeabilized cells retain sufficient
Ran to facilitate exportin 5-mediated AR export. Exportin 5 and
DNA-PK appear to function in distinct export pathways
because NU7026 blocked AR export and AR phosphorylation
(based on gel shift), but the inhibitor failed to block exportin
5-dependent export in the permeabilized cell setting (Fig. 10C).

DISCUSSION
We developed a digitonin-permeabilized cell assay to analyze
nuclear export of AR from LNCaP cell nuclei. Permeabilized
cell assays have been used to purify and characterize cytosolic
transport factors that function in a variety of nuclear import
and export pathways. Unexpectedly, we found that an energyregenerating system together with short dsDNA oligonucleotides, like those typically used for electrophoretic mobility shift
assay, stimulated efficient AR export. The fact that AR export in
this assay does not require the addition of cytosol may indicate
that nuclei of digitonin-permeabilized cells retain sufficient levels of transport factors needed for this export pathway. A similar observation was made in the context of the in vitro nuclear
export of NFAT (31). Alternatively, AR may not require a clas-

FIGURE 9. NU7026 enhances transcription of androgen-responsive genes
in LNCaP cells. LNCaP cells were treated with 10 M NU7026 for 16 h and then
treated with or without R1881 for an additional 24 h at the concentrations
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shown. Transcription of PSA (A), S100P (B), FKBP51 (C), and PDF (D) genes was
then monitored using real time RT-PCR. Transcript levels were normalized to
those of ␤-glucuronidase, and this ratio is plotted as the means ⫾ S.E. SQ,
starting quantity.
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FIGURE 10. Exportin 5 stimulates AR export in vitro. A, LNCaP cells were
treated with 10 nM R1881 prior to standard in vitro export assays in the presence of ERS, OA, and/or recombinant human exportin 5 (0.1 or 0.2 mg/ml) as
shown. Exported AR fractions were immunoblotted with PG-21. In lanes 2 and
4, dialysate obtained from the purification of recombinant exportin 5 was
added to the export reaction mix as a negative (buffer) control. B, standard in
vitro export reactions were conducted in the presence of ERS, recombinant exportin 5 (1 M), and recombinant GST-DBD-Hinge (10 M) as
shown. C, LNCaP cells were treated with 10 nM R1881 alone or in combination with 2.5 M NU7026 prior to standard in vitro export assays in the
presence of ERS, OA, ARE (100 nM), and/or recombinant exportin 5 as
shown.

sical export receptor for nuclear export via this pathway. The
permeabilized cell assay enabled us to identify several biochemical features of AR export in vitro. These include the following,
1) dsDNA oligonucleotides potently stimulate AR export. 2)
This AR export pathway requires ATP hydrolysis. 3) dsDNAdependent export is blocked by the DNA-PK inhibitor
NU7026. 4) Ligand dissociation is not a prerequisite for AR
export. 5) AR export can also be stimulated by the export receptor exportin 5.
Energy Requirements for dsDNA-dependent AR Export—
dsDNA-dependent AR nuclear export requires nucleotide
hydrolysis based on our finding that ATP, but not the nonhydrolyzable analog AMP-PNP, supports AR export. In our assay,
ATP may serve primarily as a substrate for DNA-PK, another
nuclear kinase(s), and/or a molecular chaperone(s). Yang et al.
(32) found that ATP hydrolysis is necessary for robust GR
export in digitonin-permeabilized cells when tyrosine phosphorylation is stabilized, consistent with an ATP requirement
by a nuclear tyrosine kinase involved in GR export. ATP is also
rate-limiting for the in vitro export of NFAT (31) and the
human immunodeficiency virus, type 1, protein Rev (29). However, the identities of the ATP-utilizing enzyme(s) in these systems remain undefined. Elbi et al. (48) found that ATP is necessary for the chaperone-mediated restoration of the
intranuclear mobility of GR and PR in permeabilized cells, but
in that study the relationship between ATP utilization, nuclear
receptor mobility, and nuclear export was not examined.
Stavreva and co-workers (49) found that GFP-GR recycling on a
APRIL 18, 2008 • VOLUME 283 • NUMBER 16

mouse mammary tumor virus promoter array in live cells is
sensitive to energy depletion and to the hsp90 inhibitor
geldanamycin. These findings with GR imply that ATP may
also be utilized by a chaperone(s) for successful interactions
with AR prior to AR nuclear export. However, hsp90 is not the
most likely candidate because geldanamycin does not inhibit
AR export in our assay.3
GTP does not support, and GMP-PNP does not inhibit, dsDNAdependent AR export in permeabilized cells. At face value these
data suggest that dsDNA-dependent AR export is independent
of GTP-utilizing enzymes such as Ran, a stoichiometric component of numerous export receptor-cargo complexes. But
GTP hydrolysis by Ran is not required for efficient export of a
classical NES-containing cargo (33, 50), and Ran-GMP-PNP
can stimulate NES export by promoting export complex assembly. It is possible that the level of Ran-GTP remaining in our
cells following permeabilization is sufficient to promote formation of AR export complexes. Alternatively, dsDNA-dependent
AR export may not require either a classical export receptor or
RanGTP. Ran has been reported to bind AR and enhance AR
transactivation in luciferase reporter assays (51), but the relationship between these observations and our export data is not
clear.
Ligand Occupancy and AR Export—NR export is often studied in the context of receptor movement from nucleus to cytoplasm after cognate ligand has been added and subsequently
withdrawn (11, 37, 38, 52). Using our permeabilized cell assay,
we were able to test whether ligand dissociation is a prerequisite
for AR export. Using a radiolabeled synthetic androgen, we
found that AR can remain agonist-bound during dsDNA-dependent nuclear export. Thus, AR can undergo both import
(11, 53) and export (this study) while bound to agonist, and
agonist dissociation is not an absolute prerequisite for AR
export.
AR Export and Phosphorylation—Defranco et al. (34)
observed that the phosphatase inhibitor okadaic acid (100 nM)
promotes the cytoplasmic accumulation of GR in cultured cells,
which implies that a kinase/phosphatase cycle influences the
nucleocytoplasmic localization of GR. We applied OA to our
permeabilized cell assay to determine whether AR export is
regulated by a kinase/phosphatase cycle, and we observed a
modest (⬃2-fold) enhancement of ERS/ARE-stimulated AR
export. Under this condition AR is clearly phosphorylated
because it undergoes an electrophoretic mobility shift that can
be reversed by alkaline phosphatase treatment. This suggests
that direct phosphorylation of AR could be one of the ratelimiting steps for AR export in vitro. AR is phosphorylated on
multiple serines (54, 55) and on at least one tyrosine (56). Phosphorylation of Ser-650 in the hinge region positively regulates
AR internuclear migration in a heterokaryon assay (27). However, Ser-650 phosphorylation does not appear to regulate
dsDNA-dependent export in vitro, because AR containing an
alanine substitution at this position still undergoes nuclear
export and electrophoretic mobility shift in response to ARE
addition in permeabilized PC-3 cells (data not shown). Alterna-

3

L. C. Shank and B. M. Paschal, unpublished observations.
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tively, phosphorylation of a factor(s) other than AR may be
rate-limiting for dsDNA-dependent AR export.
Phosphorylation is thought to regulate the nuclear export of
nuclear receptors in addition to AR, but thus far a common
mechanism has not emerged. GR undergoes export in response
to UV irradiation in a pathway that depends on JNK phosphorylation of Ser-226 in the AF-1 region (57). GR export in
response to UV treatment can be inhibited by leptomycin B,
which provides evidence that the export receptor Crm1 mediates GR export in this setting. GR lacks a prototypical NES of
the type recognized by Crm1, suggesting the interaction either
is mediated by an adaptor protein(s) and/or involves a unique
export signal in GR. As GR export can be leptomycin B-insensitive in nonirradiated cells (52) and can be mediated by the
chaperone calreticulin (37), NR export probably occurs by
more than one pathway (reviewed in Ref. 58). PR export appears
to be mediated by Crm1 via a mechanism that is dependent on
ERK (extracellular signal-regulated kinase) phosphorylation of
Ser-294 in the AF-1 region of PR (59). It has also been reported
that cytoplasmic localization of the estrogen receptor is regulated by phosphorylation of Thr-311 in the AF-1 region of the
receptor (60). It is interesting that AF-1 phosphorylation
appears to play a role in the nucleocytoplasmic localization of
multiple NRs, given that AF-1 sequences exhibit a high degree
of variability among different nuclear receptors.
DNA Oligonucleotide Stimulation of AR Export in Vitro—
One of the major findings of this study is that short dsDNA
oligonucleotides potently stimulate nuclear export of AR. The
logic behind the introduction of the ARE oligonucleotide (containing an ARE) into the permeabilized cell assay was based on
the assumption that AR is subject to nuclear retention through
DBD-mediated binding to chromatin, and that titration of this
reaction by ARE addition should enhance AR export. The
absence of a correlation between GFP-AR nuclear mobility (t1⁄2
values) and the amount of GFP-AR nuclear export, across different export reaction conditions, suggests that ARE do not
merely relieve AR nuclear retention. Theoretically, ARE could
bind directly to the DBD of AR and induce changes in AR conformation and/or subnuclear localization to promote AR
export. ARE could also stimulate AR export by activating a
nuclear kinase that phosphorylates AR and/or another component(s) of this AR export pathway. Nuclear kinases that can be
activated by DNA include the phosphoinositide 3-kinase-related protein kinase subfamily members ATM, ATR, and DNAPK. We addressed the potential contributions of these kinases
to ARE-induced AR export by pharmacological inhibition.
Wortmannin and LY294002 inhibit ATM, ATR, and DNA-PK,
and both inhibitors were highly effective at reducing AR export
in permeabilized cells. We next utilized the inhibitor NU7026
because the IC50 values of this compound allow discrimination
between the involvement of DNA-PK (0.23 M), ATM (⬎100
M), and ATR (⬎100 M) (44). NU7026 inhibited AR export
and phosphorylation induced by ERS/OA/ARE (Fig. 8), indicating that DNA-PK activity is limiting for this pathway of AR
export. Although ARE and the other dsDNA oligonucleotides
used in this study provide means for the artificial activation of
DNA-PK, it is possible that this form of activation mimics an
activation step that occurs when DNA-PK holoenzyme is
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bound to chromatin in the context of live cells (see below).
There is also a pathway for the activation of DNA-PK endjoining activity that involves inositol phosphate binding to the
Ku regulatory dimer (61), an interesting finding in light of the
fact that inositol phosphates co-regulate certain export pathways (62, 63).
The activities of oligonucleotides of differing sequence and
structure in our export assay appeared to corroborate results
obtained with NU7026. Neither single-stranded DNA component of the ARE dsDNA oligonucleotide stimulated AR export,
consistent with the inability of single-stranded DNA to stimulate DNA-PK activity (40, 45, 64). dsRNA oligonucleotides
failed to stimulate AR export (data not shown) and do not stimulate DNA-PK activity (42, 45). Perhaps most compelling was
our finding that AR export and phosphorylation were stimulated by nonspecific dsDNA that do not contain an ARE, and
these effects were inhibited by NU7026 (Fig. 8). As discussed
below, the effects of dsDNA on AR export could be a mimetic of
DNA exposed during transcription, but it is also possible that in
our system dsDNA acts as a biochemical surrogate for some
other DNA-PK activation mechanism that has not been
described.
DNA-PK is best known for roles in DNA damage response
and V(D)J recombination (20), but multiple studies have implicated DNA-PK in pathways of nuclear receptor function.
DNA-PK has been shown to physically interact with estrogen
receptor ␣ (22), vitamin D3 receptor (23), PR (24), and AR (19).
Subunits of the DNA-PK complex have been localized by chromatin immunoprecipitation to promoters regulated by vitamin
D3 receptor (23) and AR (19). Furthermore, DNA-PK can phosphorylate GR (25) and PR (24). It is interesting to note that
DNA-PK phosphorylates PR (24) and GR (25) in the DBD/
hinge region, and AR contains a DNA-PK consensus phosphorylation site in its hinge region (Ser-656). In an early study of PR
phosphorylation it was noted that HeLa nuclear extract contains a kinase that phosphorylates PR in response to addition of
plasmid DNA harboring a progesterone-response element (65).
Together, these data suggest that at least one general mechanism of transcriptional regulation by DNA-PK involves direct
phosphorylation of nuclear receptors; this function appears to
extend to other transcription factors and RNA polymerase II
(66, 67). Exactly how DNA-PK regulates transcription has not
been elucidated, but it has been proposed to promote recycling
of AR by directing re-initiation (19). Knockdown of the Ku70 or
Ku80 subunit of the DNA-PK complex caused a modest reduction in androgen-dependent transcription of the PSA gene (19).
Using a pharmacological approach, we found that inhibiting
DNA-PK catalytic activity with NU7026 increased AR-dependent transcription from several genes. It is possible that DNA-PK
has both positive and negative roles in AR-dependent transcription, and that reducing Ku70/80 levels by knockdown and
inhibiting catalytic activity with NU7026 are not equivalent in
terms of DNA-PK inactivation.
Exportin 5 Stimulates AR Export—Virtually all proteins that
undergo nuclear transport rely on transport receptors to mediate their translocation through the NPC (47). Nuclear localization sequences have been defined in most NRs, and several
import receptors are able to mediate the nuclear import of GR,
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FIGURE 11. A model of how DNA-PK may regulate AR nuclear export. In
this model, DNA-PK becomes activated (*DNA-PK) via interaction with DNA
and mediates a phosphorylation licensing of AR. This licensing can be
blocked by the DNA-PK inhibitor NU7026 or stabilized by the phosphatase
inhibitor OA. AR licensing could then facilitate engagement with an exportin,
resulting in formation of an export complex that translocates through the
NPC. Cells may also contain a DNA-PK-independent pathway that operates
through exportin 5. See the text for further details.

including importin ␣ and importin 7 (68). Our previous work
on GR showed that the DBD contains the information that is
sufficient to specify export of a reporter protein to the cytoplasm (16). This observation, together with the finding that
mutations in the DBD of GR and AR interfere with reporter
protein nuclear export (16), leads us to propose that the NES in
nuclear receptors is encoded by the DBD. Using binding assays
we found that several exportins bind to a fragment of AR containing its DBD and hinge domains (data not shown). We tested
recombinant exportins 4 –7 in our permeabilized cell assay and
found that recombinant exportin 5 can stimulate AR export.
Furthermore, this effect can be inhibited by excess AR GSTDBD-Hinge protein. These results are consistent with exportin
5 mediation of AR export in permeabilized cells via binding to
the DBD.
Working Model for AR Export—In this study we have shown
that DNA-PK activity is critical for dsDNA-dependent AR
export. The primary function of exogenous dsDNA oligonucleotides in our permeabilized cell assay may be to provide a
surrogate activation mechanism for DNA-PK in place of activation mechanism(s) normally operational in live LNCaP cells.
Alternatively, dsDNA may both activate DNA-PK and bind
directly to AR as a means of enhancing AR export (see Ref. 29).
DNA-PK appears to function at an early step in the dsDNA-dependent AR export pathway (see Fig. 6C). Furthermore, nonspecific oligonucleotides that do not contain an ARE can stimulate AR export (see Fig. 8), Together, these results suggest that
if dsDNA both activate DNA-PK and bind directly to AR,
DNA-PK activation would occur before direct AR:oligonucleotide binding.
Our current and previous findings together with data from
other laboratories prompted us to speculate that phosphorylation may provide AR with a license to undergo export from the
nucleus in the dsDNA-dependent export pathway (Fig. 11,
Stage I). Based on the fact that DNA-PK and AR can be localized
to the same regions of the PSA promoter by chromatin immunoprecipitation (19), DNA-PK could phosphorylate AR when
APRIL 18, 2008 • VOLUME 283 • NUMBER 16

both proteins are engaged with chromatin. We speculate that
the signal for DNA-PK activation could be DNA that is exposed
during chromatin remodeling. This would provide a means of
coupling AR participation in transcription with subsequent AR
export. AR could receive its license to leave the nucleus after a
single round or after multiple rounds of transcription, depending on the gene involved and the influence of OA-sensitive
phosphatases. In this model, phosphorylated AR is expected to
co-assemble with export factors after receiving its export
license (Fig. 11, Stage II). Following assembly, an AR-exportin
complex would translocate through the central channel of the
NPC and enter the cytoplasm where the complex is disassembled (Fig. 11, Stage III). Exportin 5 does not appear to function
within this dsDNA-dependent export pathway, as a DNA-PK
inhibitor did not block exportin 5-mediated export. Finally, the
model emphasizes direct phosphorylation of AR as the event
that provides the license to leave the nucleus, but it remains
possible that DNA-PK phosphorylates an AR-interacting factor
that, in turn, regulates AR export.
The fact that dsDNA-dependent AR export can be stimulated without adding export factors clearly indicates that permeabilized cells retain sufficient quantities of these factors,
such that they are not rate-limiting in our assay. It is formally
possible that AR engages directly with the NPC without the aid
of transport factors, but given the mobility of AR in the nucleus,
it is difficult to envision how AR export regulation would be
achieved. Finally, neither the DNA-PK-dependent nor the
exportin 5-dependent export pathways required the addition of
RanGTP. In addition, GTP was not required for AR export
stimulated by the addition of dsDNA. These data imply these
pathways are Ran-independent or that residual levels of
RanGTP are sufficient to promote export. The fact that the
highly specific DNA-PK inhibitor NU7026 enhances AR-dependent transcription in LNCaP cells can be viewed as evidence
that DNA-PK negatively regulates AR activity. A simple interpretation of this result is that inhibition of DNA-PK increases
the nuclear dwell time of AR or that it increases the pool of AR
that can reinitiate transcription. The extent of the NU7026
effect on AR transcription is gene-dependent, which is interesting in light of our recent finding that the nuclear concentration
of AR required for efficient transactivation is not the same for
all AR-regulated genes (69). Rigorous evaluation of the export
license model will require defining the DNA-PK phosphorylation site(s) on AR and determining how these modifications
contribute to interactions with the nuclear export machinery.
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